FIELD: biotechnologies.
SUBSTANCE: invention relates to compositions containing vasoactive intestinal peptide (VIP) or its fragments, and to application of such compositions in treatment of aorta fibrosis.
EFFECT: group of inventions is effective in treatment and prophylaxis of aorta fibrosis.
10 cl, 4 dwg, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITIONS AND METHODS OF TREATING RENAL DISORDERS | 2009 |
|
RU2519124C2 |
| PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF HEART FAILURE | 2018 |
|
RU2788124C2 |
| ANTIBODIES SPECIFIC TO MMP9 | 2015 |
|
RU2714043C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING AN ANTIBODY SPECIFICALLY BINDING WITH THE N-TERMINAL OF LYSYL-TRNA SYNTHETASE AS AN EFFECTIVE INGREDIENT FOR THE PREVENTION OR TREATMENT OF DISEASES CAUSED BY CELL MIGRATION | 2018 |
|
RU2749591C1 |
| ANTIBODY SPECIFICALLY BINDING TO N-TERMINAL REGION OF LYSYL-TRNA-SYNTHETASE EXPOSED ON CELL MEMBRANE | 2018 |
|
RU2739393C1 |
| SCFV-FC DIMERS WHICH BIND TO THE TRANSFORMING GROWTH FACTOR β1 WITH HIGH AFFINITY, AVIDITY AND SPECIFICITY | 2016 |
|
RU2733286C2 |
| METHODS OF TREATING TISSUE CALCIFICATION | 2015 |
|
RU2770698C2 |
| ANTIBODIES TO CD40 AND METHODS OF USE THEREOF | 2016 |
|
RU2715597C2 |
| FGF21 Fc FUNCTION PROTEIN, GLP-1 Fc FUNCTION PROTEIN AND COMBINED THERAPEUTIC AGENT INCLUDING THEM AND THEIR USE | 2020 |
|
RU2804335C2 |
| ANTIBODIES, THEIR APPLICATION AND METHODS OF APPLICATION | 2016 |
|
RU2725221C2 |
